A teratoma is not alive in the sense a person or an animal is alive. It is living tissue — a clonal mass of your own cells that has escaped normal development — but it has no independent organism, no coordinated body plan, no metabolism of its own beyond what any dividing cell has, and no capacity to survive outside a host. It is best described as a developmental accident wearing the costume of an organism: it grows hair, teeth, bone, and glandular tissue because its cells retain the embryonic ability to form all three germ layers. About 1 in 3 ovarian teratomas contains recognizable teeth, and roughly 1 in 10,000–1 in 40,000 pregnancies produces a fetus-like teratoma, which is where the mythology comes from.
The developmental mechanism behind a teratoma
A teratoma begins with a single cell that still holds the full developmental toolkit — the pluripotent capacity to become any tissue type in the body. Most teratomas arise from germ cells, the egg or sperm precursors that are already programmed to build an entire organism. When such a cell escapes normal regulation and begins dividing without a body plan to guide it, it does what embryonic cells do by default: it differentiates into whatever tissues its local environment and genetic wiring permit.
The result is disorganized tissue from all three embryonic germ layers — ectoderm (skin, hair, teeth, neural tissue), mesoderm (bone, cartilage, muscle, fat), and endoderm (respiratory and gut lining, thyroid tissue). This tri-layer composition is the defining pathological feature. A 2019 review in the journal Cells notes that mature teratomas are the most common germ cell tumor in women under 40, accounting for roughly 95 percent of all ovarian germ cell tumors, and about 1 to 2 percent of all ovarian tumors overall.
In plain terms: the tumor is not assembling an organism. It is running fragments of the embryonic instruction manual with the index pages torn out.
Why a teratoma is not an organism: the five missing criteria
Biologists generally define life by a cluster of criteria: cellular organization, metabolism, growth, reproduction, response to stimuli, homeostasis, and evolution by natural selection. A teratoma meets some and fails the ones that matter most.
It has cellular organization, growth, and metabolic activity — it consumes glucose, imports oxygen, and can even grow its own blood supply through angiogenesis. But it cannot reproduce as an independent entity, cannot maintain homeostasis at a whole-body level, has no heritable population that evolves, and cannot survive detached from a host. Its blood supply is borrowed from surrounding tissue; its waste is cleared by the host's circulation.
The closest comparison is a cell culture or an organoid: living, metabolically active, but not an organism. The difference is that a teratoma is self-assembling and unregulated, which is what makes it clinically dangerous even while remaining biologically dependent.
| Criterion of life | Teratoma | Whole organism |
|---|---|---|
| Cellular organization | Yes, disorganized tissues | Yes, organized body plan |
| Metabolism | Yes (host-supplied) | Yes (self-supplied) |
| Growth | Yes, often uncontrolled | Yes, regulated |
| Independent reproduction | No | Yes |
| Homeostasis | No | Yes |
| Survival without host | No | Yes |
| Evolutionary capacity | No | Yes |
Quantified context: how common and how fast
Teratomas are rare but not vanishingly so, and the numbers matter because they set the clinical stakes. Mature cystic teratomas (dermoid cysts) account for roughly 10 to 20 percent of all ovarian neoplasms in adults, with a peak incidence in women aged 20 to 40. Malignant transformation occurs in about 1 to 2 percent of mature teratomas, most often into squamous cell carcinoma, and that risk rises with age — a 2017 study in Gynecologic Oncology found transformation risk exceeded 10 percent in women over 50.
Growth rates are slow and variable. Most mature cystic teratomas enlarge by roughly 1 to 2 millimeters per year, which is why many are found incidentally on imaging done for unrelated reasons. Teratomas in the testis behave differently: they are rare in children but account for about 5 percent of testicular tumors in adults, and in men they carry a higher malignant potential.
In newborns, sacrococcygeal teratomas are the most common tumor of infancy, occurring in about 1 in 35,000 live births, with a female-to-male ratio of roughly 3 to 1. Most are benign but can grow large enough to compromise fetal blood flow.
The time course of a teratoma: from cell to diagnosis
| Stage | Typical timing | What is happening |
|---|---|---|
| Initiation | Germ cell escapes regulation, often in utero or early adulthood | A single pluripotent cell begins unregulated division |
| Latent growth | Months to years | Slow enlargement, often asymptomatic |
| Tissue differentiation | Throughout growth | Hair, bone, teeth, and glandular tissue form |
| Detection | Incidental imaging or palpable mass | Ultrasound or CT reveals mixed cystic and solid components |
| Transformation (if it occurs) | Decades after formation, more common after age 50 | Benign tissue becomes malignant, most often squamous cell carcinoma |
| Treatment | At diagnosis | Surgical removal is definitive for mature tumors |
| Recurrence window | First 2 to 5 years after surgery | Surveillance imaging in malignant or incompletely resected cases |
Teratoma variations and edge cases
Not all teratomas are alike, and the differences drive both biology and prognosis. Mature teratomas are fully differentiated and usually benign, while immature teratomas contain embryonic tissue, most often neural, and are graded 1 to 3 by how much immature tissue is present. Immature teratomas are more common in younger women and carry a higher risk of recurrence.
A rare variant called a fetiform teratoma, or homunculus, contains a rudimentary body-like structure with a head, limbs, and even a heart-tube organization. These are not identical twins; they are a highly organized but non-viable developmental artifact. They occur in roughly 1 in 10,000 to 1 in 40,000 ovarian teratomas, depending on the case series. This is where historical claims of "pregnant women carrying a fetus in the abdomen" largely originate, and it is the source of persistent misconception.
A related entity, the teratocarcinoma, combines teratoma tissue with a malignant embryonal carcinoma component. These behave far more aggressively than mature teratomas and require chemotherapy.
Misconceptions that persist
The most common misconception is that a teratoma is a "parasite" or a "twin." Neither is accurate. A teratoma is a clonal outgrowth of the host's own cells, not a separate organism that invaded or was absorbed. Genetically, it is host tissue. Its tissues are not a person, a potential person, or a developmental sibling.
A second misconception is that all teratomas are benign. Mature cystic teratomas are usually benign, but immature teratomas and transformed mature teratomas are not. The 1 to 2 percent transformation figure for mature teratomas is important: it means roughly 1 in 50 to 1 in 100 mature ovarian teratomas harbor malignancy, and the risk climbs steeply with age.
A third misconception is that a teratoma grows hair because it "contains a baby's genetic code." It grows hair because ectodermal differentiation produces follicles, which are normal tissue types made by cells that have forgotten where they are.
What to actually do if a teratoma is suspected
- Get imaging with transvaginal ultrasound first; teratomas show characteristic mixed cystic and solid components, often with echogenic areas of fat or bone.
- Do not assume a dermoid cyst is "just a cyst." Discuss the 1 to 2 percent transformation risk with your clinician, especially after age 50, where the risk exceeds 10 percent.
- Ask whether serum tumor markers such as alpha-fetoprotein and human chorionic gonadotropin were checked; these help distinguish mixed germ cell tumors.
- Surgery is definitive for mature teratomas, and laparoscopic removal with ovarian preservation is standard for benign cases per gynecologic oncology guidelines.
- If the pathology report shows immature tissue, ask about grading and whether postoperative surveillance or chemotherapy is indicated.
- Report rapidly enlarging masses, new pelvic pain, or weight loss promptly; rapid growth is a red flag for malignant transformation.
Limitations of the current science
The biology of why some cells escape regulation while others do not remains incomplete. The molecular triggers of teratoma initiation are poorly understood, and there is no reliable way to predict which benign teratomas will transform. Most of what is known comes from surgical pathology series rather than prospective trials. The 1 to 2 percent transformation figure is drawn from large retrospective cohorts, and case series vary widely in how they define "malignant transformation."
The question of whether a teratoma is alive has a clean biological answer, but the edges — fetiform variants, mixed tumors, and long-term behavior — remain areas where the science is still catching up to the mythology.